Antioxidant nutrients protect against cyclosporine A nephrotoxicity

被引:62
作者
Cid, TP
García, JRC
Alvarez, FC
de Arriba, G
机构
[1] Hosp Univ Guadalajara, Unidad Invest, Guadalajara 19002, Spain
[2] Univ Alcala de Henares, Dept Med, Madrid, Spain
关键词
cyclosporine A; reactive oxygen species; thromboxane; free radicals; eicosanoids; lipid peroxidation; vitamin E; thiobarbituric acid reactive substances (TBARS);
D O I
10.1016/S0300-483X(03)00156-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The immunosuppressive drug cyclosporine A (CsA) has been successfully used in several diseases with immunological basis and in transplant patients. Nephrotoxicity is the main secondary effect of CsA treatment. Although the mechanisms of nephrotoxitity are not completely defined, there is evidence that suggests the role of reactive oxygen species (ROS) in its pathogenesis. It has been demonstrated in numerous in vivo and in vitro experiments that CsA induced renal failure and increased the synthesis of ROS, thromboxane (TX) and lipid peroxidation products in the kidney. Furthermore, CsA modified the expression and activity of several renal enzymes (ciclooxygenase, superoxide-dismutase, catalase and glutathione-peroxidase). Antioxidant nutrients (e.g. Vitamins E and C) can neutralize some of the effects that CsA produced in the kidney. Thus, Vit E inhibited the synthesis of ROS and TX and the lipid peroxidation process induced by CsA in kidney structures. Antioxidants can also improve renal function and histological damage produced by CsA administration. Although there are few data in humans treated with CsA, the possibility exists that antioxidants can also neutralize CsA nephrotoxicity and LDL oxidation. Thus, antioxidant nutrients could have a therapeutic role in transplant patients treated with CsA. (C) 2003 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:99 / 111
页数:13
相关论文
共 77 条
  • [1] Effect of cyclosporin on liver antioxidants and the protective role of vitamin E in hyperoxaluria in rats
    Adhirai, M
    Selvam, R
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 1998, 50 (05) : 501 - 505
  • [2] AHMED SS, 1993, J PHARMACOL EXP THER, V265, P1047
  • [3] APANAY DC, 1994, TRANSPLANTATION, V58, P663
  • [4] GLOMERULAR HEMODYNAMICS AND HORMONAL PARTICIPATION ON CYCLOSPORINE NEPHROTOXICITY
    BARROS, EJG
    BOIM, MA
    AJZEN, H
    RAMOS, OL
    SCHOR, N
    [J]. KIDNEY INTERNATIONAL, 1987, 32 (01) : 19 - 25
  • [5] REACTIVE OXYGEN SPECIES - PRODUCTION AND ROLE IN THE KIDNEY
    BAUD, L
    ARDAILLOU, R
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY, 1986, 251 (05): : F765 - F776
  • [6] CYCLOSPORINE-ASSOCIATED HYPERTENSION
    BENNETT, WM
    PORTER, GA
    [J]. AMERICAN JOURNAL OF MEDICINE, 1988, 85 (02) : 131 - 133
  • [7] Prevention by selenium supplementation of cyclosporin-A-induced vascular toxicity
    Berkenboom, G
    Brekine, D
    Fang, ZY
    Neve, J
    Fontaine, J
    [J]. CARDIOVASCULAR RESEARCH, 1997, 33 (03) : 650 - 654
  • [8] MINIMALLY MODIFIED LOW-DENSITY-LIPOPROTEIN STIMULATES MONOCYTE ENDOTHELIAL INTERACTIONS
    BERLINER, JA
    TERRITO, MC
    SEVANIAN, A
    RAMIN, S
    KIM, JA
    BAMSHAD, B
    ESTERSON, M
    FOGELMAN, AM
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1990, 85 (04) : 1260 - 1266
  • [9] BERTY RM, 1991, J LAB CLIN MED, V118, P17
  • [10] Beveridge T, 1982, CYCLOSPORIN A, P35